Rhythm Pharmaceuticals Inc (NAS:RYTM)
$ 67.33 3.43 (5.37%) Market Cap: 4.14 Bil Enterprise Value: 3.63 Bil PE Ratio: 0 PB Ratio: 349.18 GF Score: 60/100

Rhythm Pharmaceuticals Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript

Jun 09, 2020 / 07:50PM GMT
Release Date Price: $20.91 (+0.77%)
Graig Suvannavejh
Goldman Sachs Group, Inc., Research Division - Executive Director & Senior Equity Research Analyst

Well, thank you, everyone, and welcome to the 3:50 p.m. session day 1 of the Global Healthcare Conference by Goldman Sachs. I have the pleasure this afternoon of having Hunter Smith, Interim CEO and CFO of Rhythm Pharmaceuticals; as well as Murray Stewart, who is the Chief Medical Officer. And with that, thank you both for joining us and participating in our virtual webcast this afternoon.

Maybe just to start at a very high level, maybe it's best for those who may not know Rhythm Pharmaceuticals, maybe, Hunter, if you could just provide just a brief overview maybe of Rhythm and kind of what your focus is, and maybe that's a great way for us to start.

Hunter C. Smith
Rhythm Pharmaceuticals, Inc. - CFO, Treasurer & Secretary

Sure, Graig, and thank you very much for including Rhythm Pharmaceuticals in today's conference, and thank you also to Goldman Sachs for putting on this conference. And we look forward to hopefully being

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot